Contributions
Abstract: P1065
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Objective: Explore relationships between multiple cognitive domains (CD) in people with Multiple Sclerosis (PwMS) and specific MRI identified regional brain atrophy measures.
Background: Multiple Sclerosis commonly impacts cognitive function. EDSS/MRI do not identify/quantify PwMS cognitive impairment. Traditional PwMS cognitive analysis (SDMT) utilizes one outcome measure, a computerized battery provides multiple cognitive measures. Limited evaluation of cognitive profile and disease burden can miss opportunities to identify important relationships along disability trajectory. Investigating relationships between regional atrophy measurements and increased cognitive measures (individual CD, total number of CD impaired=TCDI) can improve understanding MS impact-continuum.
Methods: Retrospective analysis utilizing standardized computerized cognitive testing (NeuroTrax, NT) and MRI brain performed in PwMS. Correlational matrix of NT CD scores [global cognitive score=GCS, memory=MEM, executive function=EXE, visual-spatial ability=VIS, verbal function=VER, attention=ATT, information processing speed=INF, motor function=MOT, and TCDI with regional atrophy measurements [inter-caudate width=CAUD, third ventricular width=THIRDV, right thalamic width=RTHAL, left thalamic width=LTHAL right thalamic/cerebral peduncle width-ratio=RTHALRAT, and left thalamic/cerebral peduncle ratio=LTHALRAT]. Multivariate linear regression analysis was used to analyze atrophy measures as potential predictors of cognitive functional ability. Significance was defined (p< 0.05).
Results: PwMS N=59, 81.4%female, average age=47.3±10.7. Significant relationships included: CAUD with GCS(p< 0.001), MEM(p< 0.000), EXE(p< 0.006), ATT(p< 0.001), INF(p< 0.002), MOT(p< 0.001), and TCDI(p< 0.000); THIRDV with GCS(p< 0.002), MEM(p< 0.000), EXE(p< 0.005), ATT(p< 0.004), INF(p< 0.001), MOT(p< 0.021), and TCDI(p< 0.000); RTHAL with GCS(p< 0.005), EXE(p< 0.001), ATT(p< 0.008), INF(p< 0.024), MOT(p< 0.000), and TDI(p< 0.002); LTHAL with EXE(p< 0.023), MOT
(p< 0.002), and TCDI(p< 0.010). No significant associations identified by linear regression analysis.
Conclusions: Multiple individual CD measures and TCDI are both highly related to the degree of multiple specific regions brain atrophy identified in PwMS. Computerized cognitive testing provides rich cognitive information and MRI brain atrophy measurements both provide patient-centric information not provided by EDSS/SDMT.
Disclosure: This study was supported by a grant from Sanofi-Genzyme
Gudesblatt M: Research support from Biogen, Teva, Sanofi-Genzyme, Novartis and EMD Serono; and speaker fees/consultant for: Biogen, Novartis, Teva, Sanofi-Genzyme, Amgen, Saol Therapeutics, Medtronic, Accorda, TG Therapeutics, EMD Serono
Wilken J: grants and personal fees from Biogen, Sanofi Genzyme and George Washington University. Fratto T: study supported by Biogen
Golan D: nothing to disclose
Sullivan C: nothing to disclose
Wissemann K: nothing to disclose
Grief E: nothing to disclose
Fafard L: nothing to disclose
Bumstead B: Speaker fees from Biogen, Genentech, Sanofi-Genzyme, and Teva.
Buhse M: Speaker fees from Sanofi-Genzyme, and Teva.
Zarif M: Speaker fees from Acorda, Biogen, Sanofi-Genzyme, and Teva
Doniger G: an employee of NeuroTrax Corporation
Abstract: P1065
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Objective: Explore relationships between multiple cognitive domains (CD) in people with Multiple Sclerosis (PwMS) and specific MRI identified regional brain atrophy measures.
Background: Multiple Sclerosis commonly impacts cognitive function. EDSS/MRI do not identify/quantify PwMS cognitive impairment. Traditional PwMS cognitive analysis (SDMT) utilizes one outcome measure, a computerized battery provides multiple cognitive measures. Limited evaluation of cognitive profile and disease burden can miss opportunities to identify important relationships along disability trajectory. Investigating relationships between regional atrophy measurements and increased cognitive measures (individual CD, total number of CD impaired=TCDI) can improve understanding MS impact-continuum.
Methods: Retrospective analysis utilizing standardized computerized cognitive testing (NeuroTrax, NT) and MRI brain performed in PwMS. Correlational matrix of NT CD scores [global cognitive score=GCS, memory=MEM, executive function=EXE, visual-spatial ability=VIS, verbal function=VER, attention=ATT, information processing speed=INF, motor function=MOT, and TCDI with regional atrophy measurements [inter-caudate width=CAUD, third ventricular width=THIRDV, right thalamic width=RTHAL, left thalamic width=LTHAL right thalamic/cerebral peduncle width-ratio=RTHALRAT, and left thalamic/cerebral peduncle ratio=LTHALRAT]. Multivariate linear regression analysis was used to analyze atrophy measures as potential predictors of cognitive functional ability. Significance was defined (p< 0.05).
Results: PwMS N=59, 81.4%female, average age=47.3±10.7. Significant relationships included: CAUD with GCS(p< 0.001), MEM(p< 0.000), EXE(p< 0.006), ATT(p< 0.001), INF(p< 0.002), MOT(p< 0.001), and TCDI(p< 0.000); THIRDV with GCS(p< 0.002), MEM(p< 0.000), EXE(p< 0.005), ATT(p< 0.004), INF(p< 0.001), MOT(p< 0.021), and TCDI(p< 0.000); RTHAL with GCS(p< 0.005), EXE(p< 0.001), ATT(p< 0.008), INF(p< 0.024), MOT(p< 0.000), and TDI(p< 0.002); LTHAL with EXE(p< 0.023), MOT
(p< 0.002), and TCDI(p< 0.010). No significant associations identified by linear regression analysis.
Conclusions: Multiple individual CD measures and TCDI are both highly related to the degree of multiple specific regions brain atrophy identified in PwMS. Computerized cognitive testing provides rich cognitive information and MRI brain atrophy measurements both provide patient-centric information not provided by EDSS/SDMT.
Disclosure: This study was supported by a grant from Sanofi-Genzyme
Gudesblatt M: Research support from Biogen, Teva, Sanofi-Genzyme, Novartis and EMD Serono; and speaker fees/consultant for: Biogen, Novartis, Teva, Sanofi-Genzyme, Amgen, Saol Therapeutics, Medtronic, Accorda, TG Therapeutics, EMD Serono
Wilken J: grants and personal fees from Biogen, Sanofi Genzyme and George Washington University. Fratto T: study supported by Biogen
Golan D: nothing to disclose
Sullivan C: nothing to disclose
Wissemann K: nothing to disclose
Grief E: nothing to disclose
Fafard L: nothing to disclose
Bumstead B: Speaker fees from Biogen, Genentech, Sanofi-Genzyme, and Teva.
Buhse M: Speaker fees from Sanofi-Genzyme, and Teva.
Zarif M: Speaker fees from Acorda, Biogen, Sanofi-Genzyme, and Teva
Doniger G: an employee of NeuroTrax Corporation